FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX‐bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34166
Abstract: After failure of first line FOLFOX‐bevacizumab for metastatic colorectal cancer (mCRC), adding either bevacizumab or aflibercept to second‐line FOLFIRI increases survival compared to FOLFIRI alone. In this French retrospective multicentre cohort, we included patients with… read more here.
Keywords: folfox bevacizumab; bevacizumab aflibercept; failure; colorectal cancer ... See more keywords
Cardiovascular and Cerebrovascular Safety of Ranibizumab, Bevacizumab, and Aflibercept in Ocular Diseases: an Analysis of the FDA Adverse Event Reporting System database (FAERS).
Sign Up to like & getrecommendations! Published in 2023 at "Journal of clinical pharmacology"
DOI: 10.1002/jcph.2244
Abstract: The cardiovascular and cerebrovascular safety of ranibizumab, bevacizumab, and aflibercept for ocular diseases is unclear. This study aimed to evaluate and compare the cardiovascular and cerebrovascular safety in patients receiving ranibizumab, bevacizumab, and aflibercept for… read more here.
Keywords: ranibizumab bevacizumab; cardiovascular cerebrovascular; bevacizumab aflibercept; bevacizumab ... See more keywords
Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema
Sign Up to like & getrecommendations! Published in 2017 at "Graefe's Archive for Clinical and Experimental Ophthalmology"
DOI: 10.1007/s00417-017-3624-y
Abstract: PurposeTo evaluate the visual and anatomical outcomes following switching therapy from bevacizumab to aflibercept in patients with persistent diabetic macular edema (DME).MethodsPatients with DME and central macular thickness (CMT) >300 μm on spectral domain optical coherence… read more here.
Keywords: bevacizumab aflibercept; bevacizumab; diabetic macular; switching therapy ... See more keywords
Efficacy and safety of brolucizumab for serous drusenoid pigment epithelium detachment non-responder to bevacizumab and aflibercept.
Sign Up to like & getrecommendations! Published in 2022 at "European journal of ophthalmology"
DOI: 10.1177/11206721221143154
Abstract: INTRODUCTION We report the case of a woman with drusenoid pigment epithelial detachment (DPED) in age-related macular degeneration who was successfully treated with two monthly intravitreal injections of brolucizumab after failing to respond to previous… read more here.
Keywords: subretinal fluid; bevacizumab aflibercept; intravitreal injections; drusenoid pigment ... See more keywords
Long-term effects of intravitreal bevacizumab and aflibercept on intraocular pressure in wet age-related macular degeneration
Sign Up to like & getrecommendations! Published in 2021 at "BMC Ophthalmology"
DOI: 10.1186/s12886-021-02076-1
Abstract: Background To evaluate the incidence of sustained elevation of intraocular pressure (SE-IOP) associated with intravitreal injections of anti-vascular endothelial growth factors (anti-VEGF) bevacizumab and aflibercept in patients with wet age-related macular degeneration (wAMD). Methods A… read more here.
Keywords: anti vegf; incidence; bevacizumab aflibercept; intraocular pressure ... See more keywords